ReiThera Srl

Nov 24, 2020

ReiThera Announces its GRAd-COV2 COVID-19 Vaccine Candidate is Well Tolerated and Induces Clear Immune Responses in Healthy Subjects Aged 18-55 Years

May 13, 2020

BARDA Provides the Sabin Vaccine Institute With an Additional $20 Million for Further Development of Ebola Sudan and Marburg Vaccines